Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

• Published in: Diabetes, obesity & metabolism Vol. 21; no. 1; pp. 129 - 135
• Main Authors: Blevins, Thomas C., Barve, Abhijit, Sun, Bin, Raiter, Yaron, Aubonnet, Patrick, Muniz, Rafael, Athalye, Sandeep, Ankersen, Michael
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2019; Wiley Subscription Services, Inc
• Subjects: Antidiabetics; biosimilar; Blood glucose; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); efficacy; Hemoglobin; Hypoglycemia; Immunogenicity; Insulin; insulin glargine; Patients; Safety; type 2 diabetes; type 2 diabetes; insulin glargine; safety; efficacy; biosimilar

Aims To assess the non‐inferiority of MYL‐1501D, a proposed biosimilar or follow‐on biological agent to marketed insulin glargine, to reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey) based on change in glycated hemoglobin (HbA1c). Materials and methods INSTRIDE 2...